Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Conditions

• Fallopian Tube Mucinous Adenocarcinoma
• Ovarian Seromucinous Carcinoma
• Platinum-Refractory Fallopian Tube Carcinoma
• Platinum-Refractory Ovarian Carcinoma
• Platinum-Refractory Primary Peritoneal Carcinoma
• Recurrent Fallopian Tube Clear Cell Adenocarcinoma
• Recurrent Fallopian Tube Endometrioid Adenocarcinoma
• Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
• Recurrent Fallopian Tube Mucinous Adenocarcinoma
• Recurrent Fallopian Tube Transitional Cell Carcinoma
• Recurrent Fallopian Tube Undifferentiated Carcinoma
• Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
• Recurrent Ovarian Clear Cell Adenocarcinoma
• Recurrent Ovarian Endometrioid Adenocarcinoma
• Recurrent Ovarian High Grade Serous Adenocarcinoma
• Recurrent Ovarian Low Grade Serous Adenocarcinoma
• Recurrent Ovarian Mucinous Adenocarcinoma
• Recurrent Ovarian Seromucinous Carcinoma
• Recurrent Ovarian Transitional Cell Carcinoma
• Recurrent Ovarian Undifferentiated Carcinoma
• Recurrent Platinum-Resistant Fallopian Tube Carcinoma
• Recurrent Platinum-Resistant Ovarian Carcinoma
• Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
• Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
• Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
• Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
• Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
• Recurrent Primary Peritoneal Transitional Cell Carcinoma
• Recurrent Primary Peritoneal Undifferentiated Carcinoma
• Refractory Fallopian Tube Clear Cell Adenocarcinoma
• Refractory Fallopian Tube Endometrioid Adenocarcinoma
• Refractory Fallopian Tube High Grade Serous Adenocarcinoma
• Refractory Fallopian Tube Mucinous Adenocarcinoma
• Refractory Fallopian Tube Transitional Cell Carcinoma
• Refractory Fallopian Tube Undifferentiated Carcinoma
• Refractory Low Grade Fallopian Tube Serous Adenocarcinoma
• Refractory Ovarian Clear Cell Adenocarcinoma
• Refractory Ovarian Endometrioid Adenocarcinoma
• Refractory Ovarian High Grade Serous Adenocarcinoma
• Refractory Ovarian Low Grade Serous Adenocarcinoma
• Refractory Ovarian Mucinous Adenocarcinoma
• Refractory Ovarian Seromucinous Carcinoma
• Refractory Ovarian Transitional Cell Carcinoma
• Refractory Ovarian Undifferentiated Carcinoma
• Refractory Primary Peritoneal Clear Cell Adenocarcinoma
• Refractory Primary Peritoneal Endometrioid Adenocarcinoma
• Refractory Primary Peritoneal High Grade Serous Adenocarcinoma
• Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma
• Refractory Primary Peritoneal Transitional Cell Carcinoma
• Refractory Primary Peritoneal Undifferentiated Carcinoma

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Biospecimen Collection — PROCEDURE
  Undergo collection of blood
• Cediranib Maleate — DRUG
  Given PO
• Computed Tomography — PROCEDURE
  Undergo CT
• Computed Tomography with Contrast — PROCEDURE
  Undergo CT with contrast
• Durvalumab — BIOLOGICAL
  Given IV
• Echocardiography Test — PROCEDURE
  Undergo ECHO
• Magnetic Resonance Imaging — PROCEDURE
  Undergo MRI
• Multigated Acquisition Scan — PROCEDURE
  Undergo MUGA
• Olaparib — DRUG
  Given PO
• Paclitaxel — DRUG
  Given IV
• Pegylated Liposomal Doxorubicin Hydrochloride — DRUG
  Given IV
• Topotecan Hydrochloride — DRUG
  Given IV

Study Details

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.

Key Dates

Start date

Jun 10, 2021

Status verified

Mar 2026

Primary completion

Jan 26, 2023

Completion

Mar 4, 2027

Study Design

Enrollment

120 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Arm I (paclitaxel, doxorubicin, topotecan hydrochloride))
  Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, or pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8 and 15 or days 1-5 per the discretion of the treating physician. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
• Experimental: Arm II (durvalumab, cediranib maleate, olaparib)
  Patients receive durvalumab IV over 60 minutes on day 1, cediranib maleate PO QD Monday through Friday, and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
• Experimental: Arm III (durvalumab, cediranib maleate)
  Patients receive durvalumab IV over 60 minutes on day 1 and cediranib maleate PO QD Monday through Friday. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.
• Experimental: Arm IV (cediranib maleate, olaparib)
  Patients receive cediranib maleate PO QD on days 1-28 and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may undergo ECHO or MUGA during screening and as clinically indicated on study. Patients also undergo collection of blood and CT with contrast during screening, and CT or MRI scans throughout the trial.

Primary Outcome Measure

Progression Free Survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months). ]

Locations (386)

Find similar trials in Anchorage, AK

Related Studies

• Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
  PHASE1 · Recruiting · National Cancer Institute (NCI) · Phoenix, Arizona
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
  PHASE2 · Recruiting · Roswell Park Cancer Institute · Buffalo, New York
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
  EARLY_PHASE1 · Recruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio